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 ABSTRACT 
 
Despite years of vaccination efforts, whooping cough, or pertussis, is not under control. 
Although immunization has greatly reduced the disease incidence, thousands of children 
die of whooping cough each year. Therefore, there is an urgent need to improve the 
available vaccines as well as our understanding of the immunological mechanisms 
required for optimal protection against pertussis. The focus of this thesis was on B-cell 
responses after pertussis vaccination within the scope of two clinical trials.  
 
The B-cell ELISpot protocol was optimized to ensure sensitive detection of B-cell 
responses. In paper I, the superiority of the novel protocol was demonstrated with regard 
to B-cell activation, detection sensitivity, antigen consumption, and assay time in 
comparison to an established protocol.  
 
The first trial evaluated the safety and immunogenicity of a novel live, attenuated, 
whole-cell vaccine named BPZE1 in a phase 1 clinical setting (reported in papers II and 
III). This vaccine strain is genetically modified and is designed for intranasal 
administration and a subsequent nonpathologic infection in the immunized subjects. The 
second trial was a phase 4 booster study of a fifth consecutive dose of an acellular 
pertussis vaccine in adolescents. Memory B-cell and serological responses are reported 
in paper IV. In both studies, strong serological and B-cell responses were detected with 
ELISA and ELISpot. Colonization was crucial for the BPZE1 study, whereas both 
antigen content and concentration influenced the responses in the booster study. 
 
Immunity against pertussis is still not fully understood. Evaluating several parameters of 
the immune response will give a better understanding of the immunological activities 
following pertussis infection or vaccination. More knowledge will enable better vaccines 
and contribute to the control of pertussis.  
 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING  
 
Kikhosta är en sjukdom som kännetecknas av frekventa och svåra hostanfall som 
avslutas med en kiknande inandning. Kikhosta kallas även för pertussis, vilket betyder 
svår hosta på latin (per - svår, tussis - hosta). Sjukdomen orsakas av bakterien Bordetella 
pertussis och drabbar alla åldrar, dock är ovaccinerade spädbarn värst drabbade. 
  
Vaccination är ett effektivt skydd mot kikhosta. Den globala introduktionen av 
kikhostevaccinet på 1950-talet ledde till en dramatisk minskning av sjukdomen. Det 
vaccin som användes var ett så kallat helcellsvaccin och bestod av hela avdödade B. 
pertussis bakterier. På 1980-talet utvecklades en annan typ av vaccin, det acellulära, som 
endast består av enstaka komponenter av bakterien och ger mindre biverkningar.  
 
Människans skydd mot kikhosta är kortvarigt, varken naturlig infektion eller vaccination 
ger ett livslångt skydd mot kikhosta. En naturlig infektion anses dock ge längre skydd än 
ett vaccin och helcellsvacciner anses generellt vara mer effektiva än acellulära vacciner. 
Individer som har genomgått en infektion eller som har vaccinerats får vanligtvis inte 
svår kikhosta om de smittas utan en mildare form av sjukdomen som kanske inte ens 
diagnostiseras eller uppmärksammas. Detta leder till att infekterade personer inte är 
medvetna om sin smittsamhet, vilket blir problematiskt om de har nära kontakt med 
ovaccinerade barn. Att öka skyddet för spädbarn och att öka vaccineffektiviteten har 
därför hög prioritet för att minska fallen av allvarlig och dödlig kikhosta.  
 
Trots hög vaccinationstäckning har man de senaste åren internationellt sett en ökning av 
kikhosta med flera dödsfall som följd. Det verkar därför som om de acellulära 
vaccinerna vi idag använder inte fungerar tillfredsställande. En effektivisering av 
nuvarande vacciner och vaccinationsprogram är därför efterfrågad. För att bättre förstå 
hur detta ska göras måste kunskapen om immunförsvarets roll ökas. För att få en bättre 
bild av detta har vi utvärderat svaret, som en viss typ av immunceller (så kallade B-
celler) ger efter vaccination mot kikhosta. B-celler skyddar mot infektioner genom att 
utsöndra antikroppar. När antikropparna binder till mikroorganismen så neutraliseras 
den, det vill säga mikroorganismen hindras från att orsaka infektion.  
 
I avhandlingen är två kliniska studier av kikhostevaccin inkluderade. Först  
utvecklade och utvärderade vi ett metodprotokoll för att mäta antalet B-celler i blod, en 
så kallad B-cells ELISpot, för att försäkra oss om att vi skulle få pålitliga resultat. Vårt 
nya protokoll visade sig vara snabbare och bättre på att påvisa B-celler än ett redan 
etablerat protokoll, så i fortsättningen användes bara det nya protokollet.  
 
 Den första kliniska studien som genomfördes innehöll ett nytt vaccin vid namn BPZE1. 
I studien prövades vaccinet för första gången på människor och vaccinets säkerhet och 
förmåga att aktivera immunförsvaret studerades. Den andra kliniska studien utvärderade 
B-cellssvaret efter en femte dos av två olika typer av acellulärt kikhostevaccin i 
ungdomar för att mäta dess effektivitet och säkerhet. Skillnaden mellan de två 
vaccinerna var antalet bakteriekomponenter och deras koncentration. En grupp fick ett 
vaccin med en komponent medan den andra gruppen fick fem komponenter i sitt vaccin. 
I båda studierna kunde vi se ett starkt B-cellssvar, vilket visar på att B-cellerna aktivt 
bidrar till det immunsvar som ses efter vaccination. 
 
Trots år av vaccination är kikhostans spridning inte under kontroll och runt  
200 000 barn i världen dör av sjukdomen varje år. Effektivare vaccin och 
vaccinationsprogram kan ge befolkningen bättre skydd och minska smittorisken för 
spädbarn. Ett annat tillvägagångssätt är att vaccinera spädbarnen och på så sätt mer 
direkt skydda dem mot smitta. Det nya vaccinet BPZE1 är tänkt att så småningom ges 
till spädbarn vid födseln för att så tidigt som möjligt kunna skydda dem mot kikhosta. 
Det kommer att dröja innan vi har full förståelse för hur vi bäst kan skydda oss mot 
kikhosta, men med tålamod och forskning kommer vår insikt om hur vi bäst löser 
problemet öka.  
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1 AIMS 
 
The general aim of this thesis was to investigate the impact of pertussis vaccines on B-
cell responses. The studies mainly focused on memory B cells, but plasmablasts and 
serological antibody levels were also evaluated.  
 
The specific aims of the papers were as follows: 
 
1. To optimize and validate a novel B-cell ELISpot protocol for high-sensitivity B-
cell detection (paper I). 
 
2. To evaluate the immunogenicity of the novel live, attenuated Bordetella 
pertussis vaccine strain BPZE1 in a phase 1 clinical trial with regard to 
serological, memory B-cell, and plasmablast responses (papers II and III).  
 
3. To assess the impact of a fifth consecutive dose of an acellular pertussis (Pa) 
vaccine on memory B-cell and serological responses in adolescents (paper IV). 
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2 STUDIES INCLUDED – AN OVERVIEW 
 
To facilitate the reading of the thesis, the studies included are summarized here.  
 
 
Optimization of a novel B-cell ELISpot assay (paper I)  
 
The sensitivity of a novel IgG B-cell ELISpot protocol was evaluated to ensure that an 
optimal B-cell ELISpot protocol was used for this research. This project was undertaken 
in collaboration with the Swedish biotech company Mabtech AB.  
 
The activating cocktail included in the novel protocol (R848 and interleukin [IL] 2) had 
previously been described but not directly compared to some of the well-established B-
cell activators. To assess the performance of the assay, the novel protocol and an 
established protocol were run in parallel to detect the antigen-specific response in eight 
subjects. Because these two protocols utilize two different detection systems – 
monoclonal antibodies for the novel protocol and polyclonal antibodies for the 
established protocol – a separate evaluation of this parameter was also performed. The 
functionality of the novel assay was established by detection of several different antigen-
specific responses as well as by an evaluation of an alternative, less antigen-consuming 
detection system.  
 
It was shown that the R848 and IL-2 cocktail was more efficient at activating B-cells 
compared to the other activators tested. The novel protocol displayed a significantly 
better detection sensitivity compared to the established protocol, despite shortened B-
cell activation time and reduced antigen consumption. Moreover, the novel protocol was 
easily adapted to five antigens, confirming its functionality.  
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B-cell responses in a phase 1 clinical trial of the novel live, attenuated 
vaccine strain BPZE1 (papers II and III) 
 
The novel live, attenuated Bordetella pertussis (B. pertussis) vaccine strain BPZE1, 
developed by a French group, was evaluated for the first time in humans in a phase 1 
clinical trial performed at the Swedish Institute for Communicable Disease Control (now 
the Public Health Agency of Sweden) in collaboration with the Karolinska Trial 
Alliance (KTA) at Karolinska University Hospital in Huddinge. The primary aim of the 
study was safety, and the secondary aim was immunogenicity.  
 
The study was designed as a placebo-controlled, dose-escalating, double-blind, 
randomized trial that included 48 subjects divided into three groups. The vaccine was 
given intranasally in droplets with 103, 105, and 107 colony-forming units (cfu) of 
BPZE1 per dose. Each group included 12 subjects that received the active vaccine (low, 
medium, or high dosage) and 4 subjects that received a placebo. None of the subjects 
had received a previous pertussis vaccination, but they were not considered naïve due to 
pertussis circulation in the population.  
 
An extensive safety follow-up was performed, and nasopharynx samples from all 
subjects were cultured for BPZE1 to determine culture positivity and colonization time. 
Blood samples were collected on days 0, 7, 14, and 28 and at 5-6 months after 
vaccination for the determination of immunological responses. Serum IgG levels and 
number of IgG-secreting plasmablasts and memory B cells were evaluated.  
 
The first-in-man study of BPZE1 showed that intranasal administration of a live, 
attenuated B. pertussis vaccine strain was safe for human use. Colonization was dose-
dependent and strong pertussis-specific antibody and B-cell responses were detected in 
subjects colonized by the bacteria.  
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Memory B-cell and serological responses after a fifth consecutive dose of 
acellular (Pa) pertussis vaccine in adolescents (paper IV) 
 
In an adolescent booster study, the immunogenicity of a fifth consecutive dose of a Pa 
vaccine was evaluated. The study was an open-label, randomized, multicentre study 
with blinded analysis. Adolescents aged 14–15 years who had previously participated in 
a Pa vaccine clinical trial during the 1990s as well as a trial evaluating the safety and 
efficacy of a Pa booster at 5½ years of age were recruited to the study [5, 6]. All had 
received a Pa vaccine consisting of five components of the bacteria at all four previous 
occasions.  
 
In total, 230 subjects were recruited to the study and randomized into groups that 
received a Pa vaccine consisting of either one or five components of the bacteria. Of the 
230 subjects, 34 had available samples for memory B-cell analysis; 18 of these subjects 
had received the 1-component vaccine and 16 had received the 5-component vaccine. 
Blood samples were collected on two occasions (day 0 and day 28–42), and three 
antigen-specific memory B-cell responses were evaluated.  
 
A fifth dose of an acellular pertussis vaccine induced significant increases of pertussis-
specific antibody levels as well as memory B-cell levels in the 34 included adolescents. 
The antigen-content and concentration did however influence the vaccine-induced 
response.  
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3 VACCINATION – A BRIEF INTRODUCTION 
 
The first vaccine was developed more than 200 years ago [7], and since its discovery 
vaccines have saved millions of lives. Immunization prevents approximately 6 million 
deaths each year [8] and is one of the most effective methods we have for disease 
prevention.  
 
The principle of immunization is to induce a strong immunological memory without 
producing a harmful and potentially fatal infection in the individual. During an infection, 
the immune system forms a pathogen-specific immunological memory that will protect 
against subsequent infections. Depending on the pathogen, this protective memory can 
last from years to a lifetime. Vaccination utilizes this immunologic capacity and 
introduces the host immune system to the pathogen under controlled, nonpathologic 
circumstances. This enables the immune system to evoke a protective memory without 
the host being afflicted with the disease.  
 
3.1 VACCINES 
Today, vaccines against a wide array of pathogens are available. Vaccines are classified 
into different types: live, attenuated; inactivated or killed; toxoid; subunit or acellular; 
and conjugate (for examples, see Table 1). 
 
Live, attenuated vaccines consist of weakened (attenuated) forms of the pathogens that 
is able to replicate without causing disease. Inactivated vaccines contain the killed, non-
replicating form of the pathogen. These two types are known as whole-cell vaccines. 
Inactivation is usually obtained by chemical treatment or irradiation to create a non-
replicating pathogen with an intact surface structure that can interact with the immune 
system. Attenuation is generally obtained using serial passage in cell lines, but the 
development of molecular techniques has allowed more controlled genetic mutations 
and deletions to be used to attenuate pathogens.  
 
Toxoid vaccines consist of a detoxified toxin (toxoid) that is used against bacteria whose 
toxin is the sole cause of illness. Detoxification is usually done through chemical 
treatment that does not affect the ability of the toxoid to interact with the immune 
system. The toxoid vaccine induces an immune response specific for the naturally 
occurring toxin.   
 
Subunit, or acellular, vaccines are similar to the toxoid vaccines in that they only 
contain purified parts of the pathogen and not the entire organism. Adhesion proteins or 
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other surface structures and toxoids are common antigens included in such vaccines. 
Acellular vaccine components are poorly immunogenic by themselves, and the vaccines 
must include adjuvants to evoke a strong pathogen-specific immunity.  
 
Conjugate vaccines are used to vaccinate small children against polysaccharide-coated 
bacteria. The immature immune system of children does not respond well to these types 
of bacteria. Therefore, the polysaccharide is conjugated to a protein to induce a strong 
immune response.  
 
Table 1. Different vaccine types and examples of available vaccines. 
Vaccine type  Includes Available vaccines 
Live, attenuated Whole organism Measles, mumps, rubella, polio (oral polio 
vaccine), influenza (intranasal), varicella, rotavirus, 
tuberculosis (BCG) 
 
Inactivated Whole organism Polio (inactivated polio vaccine), hepatitis A, 
pertussis (whole cell) 
 
Toxoid Detoxified toxin Diphtheria, tetanus 
 
Subunit/acellular Components of the 
pathogen  
Hepatitis B, pertussis (acellular), HPVa, influenza 
(parenteral) 
  
Conjugate Protein-conjugated 
polysaccharide 
Hib b, Streptococcus pneumoniae, Neisseria 
meningitidis  
aHuman papillomavirus, bHaemophilus influenzae type b 
 
 
3.2 CHILDHOOD IMMUNIZATION PROGRAM 
Currently, the World Health Organization (WHO) recommends a global routine 
childhood immunization program that includes vaccines against 12 different pathogens 
[9]. Depending on the nation-specific disease burden, this program is adapted to provide 
optimal protection in each country. In Sweden, nine of these vaccines are included in the 
general childhood vaccination program (see Table 2). Protection against mumps is also 
offered to all children in combination with measles and rubella (the MMR vaccine). The 
Swedish vaccination program also offers tuberculosis (BCG), hepatitis B, and influenza 
vaccines to children in high-risk groups. Rotavirus vaccination will also be implemented 
in the near future in some counties. The adherence to the national childhood vaccination 
program in Sweden is excellent, and more than 98% of the children are vaccinated [10]. 
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Globally, vaccines are well accepted, and vaccination coverage is around 80% in the 
world today [11]. High vaccination coverage is vital for maintaining herd immunity in 
the population, which offers protection to unvaccinated individuals. Some individuals 
cannot be immunized due to medical conditions such as immunodeficiency, but there 
are also some people that choose not to be vaccinated due to various beliefs. Anti-
vaccinationists have existed since the invention of vaccines. A cautionary example is the 
Wakefield study [12] in which MMR vaccination was falsely connected to autism. 
Although this article was retracted by the journal [13], it led to a widespread decrease of 
MMR vaccination in children and subsequent measles outbreaks due to loss of immunity 
in the population as seen, for example, in Ireland [14]. This demonstrates the fragility of 
our protection against vaccine-preventable diseases and is a reminder that many of the 
vaccine-targeted pathogens are still a threat. Therefore, it is crucial to maintain high 
vaccination coverage because this also protects those who cannot be vaccinated.  
 
Table 2. Comparison of the general childhood vaccination schedule in Sweden with WHO 
recommendations. 
Vaccine 
against Recommended by 
The general Swedish childhood vaccination 
schedule (by vaccination age)e 
 WHO Sweden 3 m 
5 
m 
12 
m 
18 
m 
5-6 
y 
6-8 
y 
10-12 
y 
14-
16 y 
Tuberculosis Yes To high-risk 
groups 
        
DTPa Yes Yes I II III  IV   V f 
Polio Yes Yes I II III  IV    
Hibb Yes Yes I II III      
Pneumococci Yes Yes I II III      
MMRc Only measles 
and rubella 
Yes    I  II   
HPVd To girls only To girls only       I+II+ 
III 
 
Rotavirus Yes In some 
counties 
        
Influenza Certain 
immunization 
programs 
To high-risk 
groups 
        
Hepatitis B Yes To high-risk 
groups 
        
a Diphtheria, tetanus, and pertussis; b Haemophilus influenzae type b; c Measles, mumps, and rubella; d Human 
papilloma virus; e m: months, y: years, f will be implemented in 2016.  
Modified from the Public Health Agency of Sweden [15] and www.who.int [9]. 
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3.3 CLINICAL TRIALS 
Before any vaccine can be introduced, it must undergo rigorous safety and efficacy 
testing both in pre-clinical models and in humans. Human trials are referred to as 
clinical trials, and they are highly regulated to protect the participants of the study.  
 
Before initiation, all clinical trials must be approved by the national Medical Products 
Agency and regional ethical review boards. Following approval, all clinical trials are 
required to register in an open international database (e.g., www.clinicaltrial.gov) [16] 
that provides public access to the study. Additionally, an Independent Data Monitoring 
Committee (IDMC) can be contracted to further ensure the safety and scientific integrity 
of the study. The IDMC consists of independent researchers with experience in the study 
field. The members advise on whether the study should be stopped prematurely due to 
risk of harm to the participants or because the study is not likely to reach its scientific 
goal. In the BPZE1 study (paper II), an IDMC was included to exclude any bias in the 
vaccine’s safety evaluation. To ensure the safety of the participants, the IDMC was 
provided with data from one dose group before it approved continuation with the next, 
higher, dose group. The IDMC also ruled that the only case of a severe adverse event in 
the BPZE1 study was not vaccine related. 
 
Ensuring participants’ safety is the key issue in all clinical trials. Enrolment in a clinical 
study is voluntary, and all participants are free to discontinue participation at any time. 
Before enrolment, subjects must receive written and oral information about the risks and 
benefits of entering the trial, their rights, and their requirements as participants. 
Following the distribution of the oral and written information, they sign an informed 
consent form to indicate that they have received the information and are willing to 
participate in the study. No subject can be included in a clinical trial without signing the 
informed consent form.  
 
Clinical trials are divided into different phases based on how far the new drug has come 
in its development. There are four phases of clinical trials [16], and these are 
summarized in Table 3. However, the criteria (stated in the table) can be adapted to suit 
the purpose of a specific trial and are, therefore, reasonably flexible. For instance, the 
BPZE1 study (papers II and III) included a placebo group, which usually is not a 
prerequisite for a phase 1 trial. The booster study (paper IV) was classified as a phase 4 
study because the included vaccines were available on the market. However, the 
subjects were recruited from a specific cohort (previous participation in two specified 
clinical trials), and this does not strictly adhere to phase 4 criteria.  
 
  9 
Clinical trials are also classified according to their masking and allocation. Trials can be 
open, single-blind, or double-blind in terms of masking and randomized or 
nonrandomized in terms of allocation [16]. In an open study, both the participant and the 
trial investigator know what type of vaccine or placebo the participant is given. In a 
single-blind study, either the participant or the trial investigator is blinded to what 
treatment is given, and in a double-blind study neither knows the intervention. The 
intervention code in double-blind trials is kept by a third party and can be broken 
prematurely following certain criteria that are set before the initiation of the trial. In 
randomized trials, the participants are allocated to the different study groups by chance 
[16]. Including masking and allocation reduces the risk of bias in the study and increases 
the reliability of the collected data.   
 
From beginning to end, a clinical trial is a time-consuming process. Due to all of the 
safety precautions and regulations, taking a new vaccine from the laboratory into the 
market requires many years and costs enormous amounts of money. However, solid 
investigation of a new vaccine in an increasing number of subjects ensures a safe 
evaluation of its risks and benefits. Maintaining the quality of clinical trials is essential 
for obtaining new and safe treatments.  
 
 
 
Table 3. General objectives and aims of clinical trials in different phases.  
Modified from [17]. 
 
 
 
Phase  Objective Number of 
subjects 
Aims 
1 Safety <100 Identify adverse events. For novel vaccines, 
immunogenicity studies are often included. 
2 Safety and efficacy 100–300 Compare efficacy (and safety) of new 
interventions with placebo and/or existing 
interventions. 
3 Confirmation of 
safety and efficacy 
>1000 Obtain more information on safety and efficacy 
in larger, more diverse populations. 
4 Long-term safety 
and efficacy 
 Post-marketing studies. Additional information 
on safety and efficacy under less controlled 
settings. “Real-life” responses. 
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4 IMMUNOLOGY  
 
The human body is constantly exposed to microbes; some of these are essential for our 
survival, but others are pathogenic. Our immune system is highly evolved to strike a 
balance between tolerating commensal microbes and fighting pathogens, and this 
homeostasis is carefully regulated. The immune system consists of several different cell 
populations, and each contributes alone and together with other cell types for efficient 
protection. Without this cooperation, we would quickly succumb to the numerous 
microbes found in our environment.  
 
4.1 THE INNATE IMMUNE SYSTEM 
Innate immunity is often described as a first line of defence against invading pathogens. 
The cells and the effector molecules of the innate response circulate in a functional state 
and are ready to rapidly respond to an invading pathogen. This local innate response can 
be sufficient to prevent infection, but adaptive immunity is usually required as well.  
 
The innate immune system is activated by recognition of different pathogen-associated 
molecular patterns (PAMPs) expressed or secreted by pathogens as well as by 
recognition of self-molecules produced by damaged or dying cells (damage-associated 
molecular patterns [DAMPs]) [2]. These PAMPs and DAMPs are recognized by a large 
number of different pattern recognition receptors (PRRs) that exist as both cell 
membrane-bound receptors and soluble receptors in the cytoplasm. Toll-like receptors 
(TLRs) are a group of PRRs that have been extensively studied. Nine well-characterised 
members of the TLR family are expressed by humans, either at the cell surface (TLRs 1, 
2, 4, 5, and 6) or in the endosomes (TLRs 3, 7, 8, and 9). The cell surface-associated 
TLRs recognise extracellular PAMPs and DAMPs, and the endosome-associated TLRs 
recognise PAMPs from phagocytosed pathogens. Upon binding, the TLRs activate 
different intracellular signalling cascades that ultimately lead to increased pro-
inflammatory responses.  
 
Cells that belong to the innate immune system contribute to the rapid clearance of 
invading pathogens, but these cells also work as part of the adaptive immune system. 
The macrophages and dendritic cells (DCs) of the innate system are so-called 
professional antigen-presenting cells (APCs). They scan the peripheral tissues in search 
of PAMPs, and upon encountering them they internalize the foreign antigen and present 
it in context with the major histocompatibility complex class II (MHCII) molecules. The 
APCs then travel to secondary lymphatic organs (SLOs), such as the spleen or lymph 
nodes, where they present the antigen and activate cells of the adaptive immune system.  
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4.2 THE ADAPTIVE IMMUNE SYSTEM 
Whereas the cells of the innate immune system respond non-specifically to PAMPs, the 
adaptive immune system is a highly specialized system where each cell has unique 
antigen specificity. Initially, the adaptive response is slower than the innate response, but 
it provides a long-term pathogen-specific immunologic memory once established. The 
adaptive immune system normally consists of two responses: the cell-mediated immune 
response and the humoral immune response.  
 
4.2.1 T cells 
T cells play a central role in the cell-mediated immune response. They are divided into 
several different subgroups, each with different effector functions. Two major groups 
are CD4+ T cells and CD8+ T cells. The major function of CD8+ T cells is to kill infected 
cells after recognising foreign antigen expressed in context with MHC class I molecules 
by nucleated cells.  
 
The CD4+ helper T cells (TH) are the regulators of the adaptive immune system [2]. 
They are activated by the recognition of an antigen bound to MHCII molecules on 
APCs. Activated CD4+ T cells orchestrate the adaptive immune response by up-
regulating co-stimulatory molecules and secreting cytokines. CD4+ TH cells are further 
divided into subgroups, including TH1 and TH2 cells, regulatory T cells (Treg), and TH17 
cells. The different subgroups secrete different sets of cytokines, and each set will in 
turn facilitate the activation of a specific immune response. The main cytokine of the 
TH1-type of response is interferon gamma (IFN-γ), which induces a response against 
intracellular pathogens. TH2 cells secrete IL-4 and IL-5, which initiate a response against 
extracellular pathogens. Treg cells promote immune tolerance to inhibit excessive 
immune responses, and TH17 cells are pro-inflammatory and associated with 
autoimmune diseases [18]. 
 
A more recent discovery is the CD4+ follicular helper T cells (TFH). They are the 
mediators of the humoral immune response and have been found in both mice and 
humans (reviewed in [19]). They reside in SLOs in close contact with B cells. By 
secreting different cytokines and co-stimulatory molecules, they promote B-cell survival 
and proliferation as well as affinity enhancement of the humoral response.  
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4.2.2 B cells 
B cells are the principal cells of the humoral response, and they exert their function 
through their effector molecules, antibodies. Antibodies, or immunoglobulins (Ig), are 
the secreted form of the B-cell receptor (BCR) and are unique to each B cell. The 
immense capacity of the B-cell population to produce antibodies with different antigen 
specificities is the key to the humoral response’s ability to combat new invading 
pathogens throughout one’s lifetime.  
 
4.2.2.1 Antibodies 
Antibodies are the effector molecules of B cells. There are five classes of antibodies: 
IgM, IgD, IgG, IgA, and IgE. IgG is the most abundant serotype, constituting 
approximately 65% of all the antibodies in sera, and has the longest half-life (9–23 
days). IgA is the predominant antibody in mucosal secretions. It is secreted as a dimer 
and is essential for toxin and pathogen clearance at the mucosal surfaces. IgA can also 
be found as a monomer in the blood.  
 
4.2.2.2 B-cell development – an introduction 
To reach full maturation and function, the B cell undergoes multiple developmental 
stages. Each B cell expresses a unique BCR with a specific antigen-binding capacity, 
and the affinity of this binding determines the efficacy of the antibody response towards 
the pathogen. The B cells are derived from the bone marrow but migrate to the SLOs 
where they undergoes further development and maturation (schematically described in 
Figure 1).  
 
4.2.3 Memory B cells and long-lived plasma cells  
Memory B cells and long-lived plasma cells (LLPCs) both express BCRs with high 
affinity and represent the classical components of the humoral response. LLPCs are 
secreted as immature plasmablasts but mature and migrate to the bone marrow where 
they continuously secrete antibodies that maintain the serological protection against 
pathogens. Memory B cells home to SLOs but can also be detected in peripheral blood. 
The memory B-cell pool is the source of the humoral anamnestic response that is 
characterized by the rapid increase of antigen-specific antibodies detected after 
reinfection. Upon reactivation, they either differentiate into antibody-secreting cells 
(ASCs) or re-enter the germinal centre reaction, which increases the antigen-specific B-
cell pool. With increasing age and with re-exposures, the memory B cells accumulate 
[20, 21], and detectable memory B cells are found many years after infection or 
vaccination [22-24].  
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Figure 1. B-cell development and maturation.  
1. In the secondary lymphoid organs (SLO), the naïve B cell is activated by recognition of 
its cognate antigen.  
2. Activation leads to internalization and MHCII presentation of the antigen as well as 
upregulation of receptors that promote follicular helper T-cell (TFH) interactions and 
further activation.  
3. Following activation, the B cell can either enter into the extrafollicular pathway or the 
germinal centre (GC) reaction. The extrafollicular pathway is the origin of short-lived 
plasma cells (SLPC) that produce antibodies with low affinity.  
4. In the dark zone of the GC reaction, two central processes in B-cell maturation take 
place: somatic hypermutation (SHM) for antibody affinity maturation and antibody class 
switch by class-switch recombination (CSR). 
5. Following SHM and CSR, the B cell migrates into the light zone of the GC reaction 
where it further interacts with TFH and follicular dendritic cells and undergoes additional 
antigen-dependent selection. High-affinity binding promotes survival, so poorly binding 
B cells are selected against. 
6. B cells with high affinity antibodies leave the GC reaction as either a nonsecreting 
memory B cell going to SLOs or as an antibody-secreting long-lived plasma cell (LLPC) 
going to the bone marrow. Adapted from [2]. 
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The humoral response has an extraordinary capacity for maintaining pathogen-specific 
protective antibody levels throughout a lifetime without any requirements for 
subsequent exposure to the pathogen or for booster vaccination [23, 25]. How this 
constant level is maintained is under debate. One theory suggests that the LLPCs are 
constantly being replenished in the bone marrow by an on-going cycle of activation and 
differentiation of memory B cells into LLPCs. The other theory proposes two separate 
paths for the memory B-cell and the LLPC responses where the two B-cell subsets act 
and contribute to immunity independently of each other.  
 
In human studies that have measured the long-term presence of serum antibody and 
memory B-cell levels present in the blood, low or no correlation has been detected [23, 
25, 26]. Other studies have also shown that memory B cells can be found in individuals 
without any detectable serum antibody levels with the same antigen specificity [27-29], 
and this supports the idea of two independently maintained populations of memory B 
cells and LLPCs. This theory is further strengthened by reports that antigen-specific 
serum antibody levels are maintained despite lack of antigen stimulation in both mice 
and humans [23, 30, 31] and that depletion of memory B cells has not been shown to 
affect the serum levels in mice [32-34]. However, one human study has found a 
correlation between long-term vaccine-induced memory B-cell and serum IgG 
responses, but the same study also detected subjects with antigen-specific memory B 
cells and no serum IgG [22]. This shows that the true relationship between the two B-
cell responses has yet to be established.  
 
4.2.4 Methods for detection of B-cell responses 
The antigen-specific cellular B-cell responses and the serological antibody responses 
reported in this thesis were measured by ELISpot and ELISA, respectively. Put simply, 
both methods are based on a similar principle in which antibodies are identified by 
binding to their specific antigen and subsequent detection steps. Furthermore, this thesis 
also includes a flow cytometry analysis reported in paper III. 
 
4.2.4.1  B-cell ELISpot 
The B-cell ELISpot (enzyme-linked immunosorbent spot) method was first described by 
Czerkinsky et.al. in 1983 [35] and is now used for evaluation of an array of different 
antigen-specific ASCs. ELISpot can be applied to both plasma cells and memory B 
cells, but detection of memory B cells requires activation and differentiation of the 
memory B cells into ASCs. This is achieved by a prestimulation step with different B-
cell activators. These activators are usually polyclonal, but specific antigens can also be 
added to the stimulation cocktail. 
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In the optimization and evaluation study of the novel B-cell ELISpot protocol reported 
in paper I, we ensured that the most optimal activation cocktail was used. Poor 
activation and differentiation of memory B cells into ASCs leads to under-reporting of 
the true number of antigen-specific ASCs present in the sample. Available B-cell 
activators target different receptors on the B cell, and several B-cell activation cocktails 
have been described [22, 36-38]. Pinna et al. [39] previously showed the potential of the 
combination of the TLR7/8 agonist R848 and IL-2 as a B-cell activator. In our study, we 
confirmed its superior induction of total IgG-producing cells compared to several other 
known B-cell activators (summarized in Table 4). We also found that the high activating 
potency of the cocktail enabled a decrease of the prestimulation time to 72 hours from 
the 6 days recommended by others [36, 37, 39]. This led us to conclude that the 
combination of R848 and IL-2 was the most optimal activator cocktail to use in the B-
cell ELISpot protocol.  
 
 
Table 4. Included B-cell activators in paper I and their effector molecule type. 
B-cell activator Type of effector molecule 
R848 TLR7/8 agonist 
CpG oligodeoxynucleotide (ODN) TLR9 agonist 
PWMa Lectin/TLR agonist 
SACb BCR cross-linking/TLR agonist 
BAFFc Cytokine 
IL-2, IL-6, IL-21, IL-10  Cytokine 
Anti-CD40 CD40 ligand 
a Pokeweed mitogen, b Staphylococcus aureus protein A, c B-cell activating factor 
 
 
The basic principle of the established B-cell ELISpot protocol is shown in Figure 2A. 
The optimized B-cell ELISpot protocol uses an amplified detection system with 
monoclonal detection antibodies (Figure 2B). We found that the monoclonal detection 
system further increased detection sensitivity as reported in paper I. 
 
We confirmed the overall performance of the novel protocol in a direct comparison with 
an established protocol [22]. A significant increase in the tetanus toxoid response in 
eight recently vaccinated subjects was detected with the novel protocol but not with the 
established protocol. Thus, the optimized protocol detects responses that otherwise 
would go undetected. The new protocol was easily adapted to several different antigens, 
and it readily detected both memory B cells and plasmablasts. We demonstrated its 
functionality and utility in papers III and IV.  
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In conclusion, the novel B-cell ELISpot protocol demonstrates a sensitive detection of 
antigen-specific ASCs, and the recent development with biotinylated antigens (paper I 
and [40]) shows that the assay can be further improved. In addition, the utility of the 
assay has been expanded for multiplex analysis through the development of the 
FluoroSpot protocol [41, 42]. 
 
 
 
Figure 2. The B-cell ELISpot protocol.  
A. The basic principle of the B-cell ELISpot. Multiscreen plates are coated with antigen. The antibody-
secreting cells are added to the well and left overnight to secrete antibodies. Only the antibodies 
specific to the coated antigen will bind. Cells and nonspecific antibodies are then washed away to 
leave only antigen-specific primary antibodies bound to the membrane. Primary antibodies are 
detected with an enzyme-conjugated secondary antibody followed by the addition of substrate and 
subsequent precipitation on the well membrane. A spot forms on the well membrane for each single 
cell. Based on the number of spots, the number of antigen-specific B cells in the sample can be 
counted.  
B. Amplified detection system. In paper I, an alternative detection system was used. This system 
utilizes two detection steps that include a secondary antibody conjugated to biotin followed by 
streptavidin-enzyme binding. This extra step amplifies the signal and enables more sensitive 
detection.  
C. Examples of well images from the B-cell ELISpot amplified detection system.  
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4.2.4.2 ELISA 
ELISA (enzyme-linked immunosorbent assay) is used to measure antibody levels in all 
types of fluids. A coating of either antigen or antibody captures the antibodies in the 
sample, and this is followed by detection with an enzyme-conjugated secondary 
antibody and colour conversion by substrate cleavage. The absorbance value of the 
sample is proportional to the amount of antibodies in the sample and is calculated by 
relating it to a reference with a known antibody concentration. The absorbance values 
are converted into either ELISA units/mL (EU/mL) or international units/mL (IU/mL) 
depending on the type of reference sera used.  
 
There are three different types of ELISA: direct, indirect, and capture (also known as 
sandwich). They are all based on the same principle but vary in their detection system 
(see Figure 3). Generally, the capture ELISA is considered the most sensitive and 
specific followed by the indirect and finally the direct ELISA. 
 
 
 
We used the indirect serum IgG ELISA in this thesis (papers II–IV). This method is 
accredited and has been used since 1992 when it was developed for laboratory use in 
collaboration with the Food and Drug Administration. Standardized methods and control 
sera enable comparison of different studies. 
 
Figure 3. Different detection systems utilized by the ELISA method.  
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A more novel approach to the ELISA is the multiplex immunoassay (e.g., Luminex) [43, 
44]. This method allows for the detection of antibodies of multiple antigen specificities 
in the same sample because antigen-coated beads are added to the sample instead of 
adding the sample to a well. This enables complex analyses on small sample volumes, 
for instance, when analysing blood samples from small children.  
 
4.2.4.3 Flow cytometry 
Flow cytometry is a multifaceted laser-based method that enables multiplex analysis of 
different cell populations within seconds. By labelling intracellular or surface 
components with fluorescent markers, the flow cytometer can detect and sort cell 
populations by their unique compositions of emitted light on a single-cell level.  
 
In this thesis, flow cytometry was used to distinguish different B-cell subpopulations 
following BPZE1 vaccination in a few subjects (paper III). Changes in expression of 
surface molecules during cellular maturation allow for identification of different B-cell 
subpopulations. To get an in-depth view of the response induced by the BPZE1 
vaccination, two flow cytometry panels were used (Table 5). This enabled detection of 
different memory B-cell subsets and class-switched B cells. B cells were first separated 
from the live peripheral blood mononuclear cell fraction by gating for CD19+, a 
universal marker for B cells. CD19 is expressed by B cells from early development but 
is lost in plasma cells. Further staining for CD27, CD21, and CD10 enabled 
identification of resting, activated, and tissue-like memory B-cell subsets (panel I). In 
panel II, CD27 and IgD staining was included to separate unswitched and switched 
memory B cells. 
 
The analysis of the subjects in the BPZE1 study indicated that the vaccine induced the 
activated memory and the tissue-like memory types of B cells. This is encouraging 
because the tissue-like memory type would indicate the peripheral response sought by 
the vaccine. It was not clear if the detected response was, in fact, pertussis-specific 
because no antigen specificity was included in the flow cytometry analysis. Antigen-
specific detection of B cells by flow cytometry is possible [45], and including this in the 
flow cytometry panels in future studies will offer more complex and comprehensive 
results from different immune responses.    
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Table 5. The two flow cytometry panels used to identify B-cell subpopulations in paper III. 
Panel I Panel II 
B cells CD19+ B cells CD19+ 
All memory B cells CD19+ CD27+ All memory B cells CD19+ CD27+ 
Transitional  CD19+ CD10+ Switched CD19+ CD27+ IgD− 
Naïve  CD19+ CD10− CD21+ 
CD27− 
Unswitched  CD19+ CD27+ IgD+ 
Activated memory  CD19+ CD10− CD27+ 
CD21low 
Naïve  CD19+ CD27− IgD+ 
Resting memory  CD19+ CD10− CD27+ 
CD21+ 
Double negatives  CD19+ CD27− IgD− 
Tissue-like 
memory  
CD19+ CD10− CD27− 
CD21− 
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5 INDUCING IMMUNITY WITH VACCINES 
 
In a recall antigen-specific response to a pathogen, the body utilizes two lines of 
immune defence (reviewed in [46]) as shown in Figure 4. For a vaccine to be efficient, 
both types of defences must be evoked. Moreover, the vaccine must induce the type of 
immune response that will give the best protection against the pathogen the vaccine is 
targeting, for example, a TH1-type of response for an intracellular organism. The 
immunological stimuli of the vaccine in combination with the local cytokine milieu will 
trigger different types of immune responses (reviewed in [46, 47]). The DCs will secrete 
different sets of cytokines depending on what PAMP/DAMP stimuli they are exposed 
to. Consequently, the vaccine content has a major influence on the type of immune 
response evoked. For whole-cell vaccines, the pathogen determines the response, but for 
acellular vaccines, the choice of adjuvants controls the type of immune response that 
will be evoked.   
5.1 ADJUVANTS 
Adjuvants are stimulatory substances that are included in vaccines to stimulate the 
uptake and presentation of the vaccine antigen. Originally, they were thought to function 
as passive depots for antigens that prolong antigen exposure to the immune system. 
Nowadays it is clear that adjuvants are important not only for inducing the immune 
responses but also for directing them. Adjuvants target the innate immune system [48] 
by functioning as PAMPs or DAMPs, and almost all PRRs are potential targets 
(reviewed in [49]). There are several on-going trials for new adjuvants [50], but there are 
only a few approved for human use: aluminium salts (alum), AS04, and oil-in-water 
emulsions (MF59, AS03).  
 
Alum is the most well-known adjuvant and has been used for many years. Alum exerts 
its immunomodulatory effect by activation of the inflammasome and release of the pro-
inflammatory cytokine IL-1 [51-53]. It has been shown to induce a TH2-skewed type of 
response [54]. AS04 is another adjuvant that contains alum in combination with the 
TLR4 agonist monophosphoryl lipid A. In contrast to alum, this adjuvant induces a TH1-
type of response [55]. 
 
MF59 and AS03 are the oil-in-water emulsions that are approved for human use. They 
are based on squalene oil and induce a mixed TH1/TH2-type of response [49]. The 
complete mechanisms of these adjuvants are not yet known, but studies have shown that 
MF59 broadens the antibody response and increases the magnitude and the functionality 
of the antibodies [56, 57].  
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Figure 4. First and second lines of immune defence in an antigen-specific recall response. 
Following a primary infection, the immune system has two lines of defence against a re-
invading pathogen. The first line functions to prevent attachment of the pathogen and 
initiation of the infection. It consists of ready-made antigen-specific antibodies present at 
the mucosal surface and in the circulation and peripheral antigen-specific effector T cells. 
However, if this line of defence fails, the second line consisting of central memory T and 
memory B cells is activated. The memory cells then rapidly proliferate and differentiate to 
prevent disease progression. Modified from [4]. 
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5.2 PARENTERAL AND MUCOSAL ADMINISTRATION 
Vaccines can be administered either parenterally (intramuscular, subcutaneous, or 
intradermal) or via the mucosa. The majority of vaccines are given parenterally, but oral 
polio and cholera vaccines as well as an intranasal influenza vaccine are available.  
 
Homing of lymphocytes is primed at the site of activation [58], which suggests that the 
choice of administration route should reflect the desired local immune response (i.e., a 
mucosal administration for a mucosal response). Nevertheless, parenteral immunization 
has been shown to induce a strong mucosal response [46]. This could be explained by 
the finding that T cells activated in the spleen display promiscuous homing patterns and 
can home to the mucosa after activation [59]. Vaccine-induced neutralizing serum IgG 
has also been shown to transude over the mucosa to contribute to the vaccine-elicited 
protection [60]. However, the contribution of serum IgG has been shown to vary at 
different mucosal sites [61-63].  
 
From the response evoked by BPZE1, it is evident that mucosal administration can 
induce a systemic IgG response with both serum antibody and memory B cells (paper II 
and III). The colonization of the attenuated vaccine strain offers a prolonged exposure of 
the pathogen to the immune system and the induction of a strong immune response. 
Mucosal administration has several advantages over parenteral-administered vaccines, 
such as needle-free administration, and the pursuit of mucosal vaccines should be 
prioritized.  
 
  23 
6 BORDETELLA PERTUSSIS 
 
Whooping cough, or pertussis, is caused by the small gram-negative coccobacillus 
Bordetella pertussis [64]. The disease is characterized by mucus-rich coughing attacks 
that end with a whooping inhalation. The first report of a pertussis epidemic is dated to 
1578 (as stated in [65]), but the microbe was not identified until the early 20th century. It 
is named after its discoverer, Jules Bordet, and the Latin word for severe cough (per – 
severe, tussis – cough). There are eight identified species of Bordetella, and four of them 
have been found in humans [64]:  
- B. pertussis, a strict human pathogen that infects the upper respiratory tract.  
- B. parapertussis, which causes a milder form of pertussis disease in humans.  
- B. bronchiseptica, which is most commonly found in animals such as dogs but 
has also been found to colonize humans.  
- B. holmesii, a rare cause of sepsis.  
 
6.1 PATHOGENESIS 
B. pertussis is sensitive and cannot survive for long outside its host. It is strictly aerobic 
and is spread by infectious aerosol droplets from coughing. It is hard to isolate and 
cultivate and requires a special growth medium containing charcoal and blood. B. 
pertussis was first believed to be an extracellular bacterium but has been shown to persist 
intracellularly ([66] and reviewed in [67]). The bacterium expresses different adhesins 
that mediate bacterial attachment to epithelial cells in the respiratory tract, including 
filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (Fim) (Figure 5). In 
addition, FHA and PRN also promote intracellular uptake and survival of the bacteria [64, 
68].  
 
B. pertussis also expresses different toxins that contribute to its pathogenesis [64]. 
Pertussis toxin (PT) is the only toxin specific to the pathogen, and it consists of five 
different subunits. The majority of the subunits enable binding of the protein, but the first 
(S1) exerts the toxicity. PT increases mucus production, which is a classical sign of 
pertussis. Adenylate cyclase toxin (ACT) has an effect similar to PT, but it also inhibits 
immune responses, which is an effect thought to be crucial for the establishment of the 
infection. Dermonecrotic toxin (DNT) causes vasoconstriction and is believed to 
contribute to the infection-inflicted tissue destruction. Tracheal cytotoxin (TCT) is an 
important contributor to the pertussis pathogenesis because it inhibits the cilia movement 
in the respiratory tract.  
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For the BPZE1 vaccine used in papers II and III, the aim was to mimic a natural infection 
without causing disease. Therefore, in the attenuation of the novel BPZE1 vaccine strain 
it was crucial to reduce the pathogenicity without losing immunogenicity. To achieve this, 
three toxins were genetically altered or removed [69]. The DNT was deleted, and the toxic 
S1 subunit of PT was mutated by two point mutations into an inactive toxin. TCT secretion 
was depleted by exchanging the ineffective B. pertussis AmpG transporter protein with 
the functional ampG gene from Escherichia coli. This reduced the TCT production by 
more than 99%. These alterations eliminated the pathogenicity of the infection (as shown 
in mouse studies) without changing the morphology of the bacteria, its adherence 
capability, or its in vitro growth rate [69] thus fulfilling the aim of inducing a 
nonpathologic infection. 
 
 
 
 
Figure 5. Virulence factors of Bordetella pertussis. Toxins: pertussis toxin (PT), tracheal cytotoxin (TCT), 
dermonecrotic toxin (DNT), and adenylate cyclase toxin (ACT). Adhesion proteins: pertactin (PRN), 
filamentous hemagglutinin (FHA), and fimbriae (Fim). Modified from Alison Weiss, ASM News, 1997. 
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6.2 CLINICAL DISEASE 
Pertussis is highly infectious and affects all people of all ages. It is estimated that 16 
million cases occur globally each year with 95% of the cases found in developing 
countries [70]. This number is most likely an underestimation because studies have 
shown that pertussis is an underdiagnosed disease [71-73]. The severe and fatal cases are 
found in the infant population, and close to 200,000 children are estimated to die of 
pertussis each year [74]. This does not include children who succumb to fatal secondary 
infections. 
 
A classical pertussis infection has three clinical stages, and it can take months for the 
affected individual to fully recover [64]. The incubation time between infection and the 
first signs of disease is quite long, 7–10 days. The catarrhal stage manifests with 
symptoms similar to a common cold, and the highest number of bacteria exists during 
this stage. This makes the individual highly contagious at the same time that the 
infection is usually mistaken for a cold, and this delays the precautions that should be 
taken to limit the spread of infection. The catarrhal stage is followed by the paroxysmal 
stage during which the classical pertussis symptoms manifest with coughing attacks 
followed by a whooping inhalation. At this stage, the bacterial toxins have inhibited cilia 
movement and increased the mucus production that lead to accumulation of mucus and 
restriction in the airways. The lack of cilia movement prevents airway clearance, and 
this initiates the coughing spasms. The spasms are often followed by the patient 
vomiting mucus. These attacks can be as frequent as 40–50 times a day leaving the 
patient exhausted. After 2–4 weeks, the paroxysmal stage recedes and the convalescent 
stage begins.  
 
Treatment against whooping cough is mostly palliative because the disease is usually 
diagnosed at a late stage when the bacteria are already cleared. B. pertussis is, however, 
sensitive to macrolides such as erythromycin, and early treatment with antibiotics can 
lead to a milder disease progression if the infection is detected in time.  
 
6.2.1 Pertussis case definitions 
Pertussis can be classified according to several different criteria into the two major 
groups of clinical pertussis and laboratory-confirmed pertussis. As the names indicate, 
the former are confirmed by clinical manifestation and the latter are confirmed by 
laboratory findings. In general, a case is referred to as a probable case if only the clinical 
criteria are met; confirmed cases also require laboratory verification [75].  
 
According to the WHO criteria for surveillance of pertussis, a clinical case is defined as 
more than 2 weeks of cough with one or more of the following symptoms: paroxysmal 
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cough, whoops, and/or post-coughing vomiting. Laboratory confirmation requires 
isolation of B. pertussis, a positive polymerase chain reaction (PCR) result, or positive 
pair serology [76]. The US Centers for Disease Control have a similar definition of the 
clinical disease, and for laboratory confirmed pertussis isolation of B. pertussis or 
positive PCR is accepted [75]. The differences between criteria (reviewed in [77]) 
hamper comparison between studies, and a harmonization of the criteria would be 
beneficial. Because pertussis disease is known to manifest differently with age, it has 
been suggested that the criteria should be age-specific [77].  
 
6.3 VACCINATION AGAINST PERTUSSIS 
Vaccines against pertussis have been available for more than 60 years and have led to a 
major decrease in pertussis incidence with a great reduction in severe and fatal cases 
[78]. Despite this, pertussis is still universally present and circulates in the population 
with cyclic peaks every 2–5 years [79].  
 
Those with a previous pertussis infection and those who have been vaccinated generally 
experience a milder and subclinical infection rendering the majority of them unaware of 
their disease [80]. Therefore, it is thought that the pertussis reservoir is harboured by 
adults and adolescents, and studies have shown that parents and other close relatives are 
the main source of pertussis transmission to infants [81-83]. An Australian study showed 
that more than 60% of the cases in a pertussis epidemic occurred in those aged ≥10 
years [84], which indicates that the major disease burden lies in the older age groups. 
Nevertheless, unvaccinated infants are the most vulnerable to pertussis, and the majority 
of the severe cases are found in this group [78, 85]. A Swedish study reported that as 
many as 72% of infected unvaccinated infants below three months of age had to be 
hospitalized due to pertussis-related complications [1].  
 
The first pertussis vaccines introduced in the late 1940s consisted of killed whole-cell 
bacteria and greatly reduced the pertussis incidence and mortality. However, whole-cell 
pertussis (Pw) vaccines have been associated with higher reactogenicity, and this led to 
the development of acellular pertussis (Pa) vaccines in the 1980s [86]. Acellular 
vaccines are available with up to five antigens of B. pertussis: detoxified PT (PTd), 
FHA, PRN, and Fim serotypes 2 and 3 (Fim2/3). Both vaccine types are recommended 
by the WHO [87]. Pa and Pw are given in combination with diphtheria and tetanus as 
part of the DTaP and DTwP vaccinations, respectively. Vaccination schemes vary 
between nations, but in general 3 or 4 doses are given during the first year of life. This 
scheme is often complimented with one or two booster doses that contain a low-dose 
diphtheria and pertussis vaccine (Tdap) [88].  
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6.3.1 Booster vaccinations 
Several studies reported a short-term efficacy of the priming doses after the introduction 
of Pa vaccines in the 1990s, and this led to a recommendation for a preschool booster 
[89-93]. There has also been a shift in pertussis incidence towards older age groups, and 
an increase has been reported in adolescents [93-95]. Therefore, the adolescent Tdap 
booster has been suggested in order to reduce the disease burden in that population. An 
adolescent booster is safe [96-103], induces long-lasting immunity [97, 104, 105], and 
successfully lowers the incidence of pertussis in that age group.    
 
The introduction of an adolescent booster was also thought to have an impact on the 
incidence of infant pertussis. However, one study investigating infant pertussis found a 
much larger transmission from other age groups than adolescents [106], and another 
group reported that the yearly peak for adolescent pertussis incidence does not coincide 
with the infant peak [83]. Moreover, a British contact study found very little interaction 
between infants and adolescents [107]. This raises questions about the effect that an 
adolescent booster will have on the infant pertussis incidence. Two studies investigating 
this have reported contradicting results. One study concluded that the introduction of the 
adolescent booster was “partially effective in preventing pertussis hospitalizations 
among infants” [108]. However, in contrast, another study concluded that the adolescent 
booster did not influence the infant pertussis incidence [109]. Although the adolescent 
booster has a positive effect on reducing pertussis incidence in that age group, the 
benefits for infant pertussis are not clear.  
 
Adolescents generally experience mild and asymptomatic pertussis infections, and a 
natural infection at that age is most likely well tolerated and would induce a longer 
lasting immunity compared to vaccination. The risk with the short efficacy of an 
adolescent Pa-booster is that it could postpone the susceptibility to pertussis into 
childbearing years and thus increase the risk of transmission to infants (discussed in [91, 
110]). In the future, a more controlled and safer approach to the natural infection could 
be to introduce the BPZE1 vaccine as an adolescent booster. With the close resemblance 
to a natural infection, the BPZE1 vaccine could offer immunity similar to a natural 
infection without the disadvantages of a wild-type infection.  
 
6.3.2 Pertussis vaccination in Sweden 
Sweden introduced Pw vaccines into the national childhood vaccination scheme in the 
early 1950s. However, Pw vaccination was discontinued in 1979 due to increasing 
reports of low vaccine efficacy and severe side effects, and this led to a rapid resurgence 
of pertussis in the population [111, 112]. With the development of the Pa vaccine, the 
safety profile of pertussis vaccination improved and vaccine efficacy trials were 
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performed in Sweden during the vaccine-free period [6, 113-115]. These studies 
confirmed the efficacy and safety of the Pa vaccines, and pertussis vaccination was 
reintroduced in 1996. The introduction led to a significant decrease in pertussis in the 
country [1] as shown in Figure 6. However, the 17-year hiatus led to a unique, natural 
immunity in the Swedish unvaccinated population when compared to other countries 
with uninterrupted pertussis vaccination programs. For the BPZE1 study, only subjects 
born during the non-vaccinating time period were included (paper II).  
 
 
 
 
 
 
Currently, Sweden employs a pertussis vaccination scheme that consists of three doses 
of either the two- or three-component vaccine at 3, 5, and 12 months. This is followed 
by a preschool booster dose at 5–6 years (introduced in 2007 after a safety and efficacy 
study [5]). In 2016 a school-leaving booster at 14–16 years of age will be introduced. 
Preceding the introduction of the adolescent booster, a safety and efficacy study was 
performed in Swedish adolescents. Specific safety data from Swedish adolescents are 
important because the effect of the hiatus in pertussis immunization on the population’s 
immunity was not clear. Some of the data obtained in this study are reported in paper 
IV.  
 
Figure 6. Incidence of laboratory-reported pertussis cases in Sweden between 1989 and 2012 in all 
age groups (left) and in infants (right). The arrow indicates the introduction of the acellular pertussis 
vaccine in combination with diphtheria and tetanus (DTaP). Modified from [1].  
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Sweden consists of 21 different counties that all implement the national immunization 
program. The vaccine brand that is used, however, is independently decided. Thus 
different pertussis vaccines are used in the country, and the brand varies over time 
within the same county. The available pertussis vaccines in Sweden are listed in Table 6. 
All vaccines are given as combination vaccines, but only the pertussis antigens are listed 
for simplicity. In paper IV, a booster vaccine named diTekiBooster was used (for the 
contents of the vaccine, see Table 7 in §7.1). This vaccine is not available on the 
Swedish market but was approved for use in the trial.  
 
 
Table 6. Available pertussis vaccines in Sweden. 
Manufacturer Brand name PTda FHAa PRNa Fim2/3a 
S.P.b  Tetravac®/Pentavac®/Hexyon 25 25 - - 
Triaxis®d 2.5 5 3 5 
GSKc Infanrix® 25 25 8 - 
Boostrix®d 8 8 2.5 - 
a Concentration of antigen (µg/0.5-mL dose), b Sanofi Pasteur, c GlaxoSmithKline, d Low-dose 
vaccine 
 
 
6.4 RESURGENCE OF PERTUSSIS 
In the last few years, there have been major pertussis outbreaks with several infant 
mortalities in countries with high vaccination coverage [116-118]. Waning immunity, 
pathogen adaptation, and better detection of the infection due to more sensitive 
diagnostics have been suggested to contribute to the increase in confirmed cases ([119, 
120] and reviewed in [121]). The global change to Pa vaccines from Pw vaccines is 
thought to be the major cause of resurgence (as discussed in [122]). A study using a 
novel baboon pertussis model [123] showed that even though Pa vaccines protected 
against disease, vaccinated animals were still colonized by the bacteria to the same 
extent as naïve animals [124]. Importantly, the Pa-vaccinated animals were also shown 
to transmit pertussis to naïve animals thus identifying a weakness of Pa vaccines. 
Convalescent animals were fully protected against colonization, but the Pw-vaccinated 
baboons were also colonized. They, however, cleared the infection more quickly 
compared to Pa-vaccinated animals. Furthermore, a study of B. bronchiseptica in its 
natural host (mice) showed that even though the Pw vaccination does not prevent 
colonization, it blocks bacterial shedding and transmission of the disease [125]. 
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In humans, Pw-primed children are less susceptible to pertussis than Pa-primed children 
[126]. Children receiving a mixed Pw/Pa vaccination schedule were also better protected 
if the first dose was Pw vaccine instead of Pa vaccine [127, 128]. The poor protective 
efficacy of Pa vaccines is, therefore, most likely to contribute to the present resurgence 
of pertussis. The pertussis vaccines available today must be improved to stop the 
resurgence of pertussis and the resulting severe and fatal cases [116, 126, 127]. 
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7 PROTECTION AGAINST PERTUSSIS 
 
A natural infection does not offer life-long protection against pertussis but instead 
induces a longer lasting protection compared to immunization. A Swedish 
seroprevalence study performed 10 years after the introduction of Pa vaccines, 
suggested that natural immunity lasts for approximately 15 years, but the protection 
gained after three doses of Pa vaccine lasts only for approximately 5 years [91, 129].  
 
7.1 VACCINE EFFICACY 
Pw vaccines are generally considered more effective than Pa vaccines [130-132]. The 
efficacy of Pa vaccines is determined by the number of components they contain. 
Vaccines including three or more components (PT, FHA, and PRN, with or without 
Fim2/3) have higher efficacy compared to 1- or 2-component vaccines ([133, 134] and 
reviewed in [135, 136]).  
 
There are many Pa vaccines on the international market, but there is no consensus 
concerning antigen concentration or adjuvants (see [137] for examples). In the booster 
study (paper IV), two different vaccines were included with varying numbers of antigens 
and antigen concentrations (see Table 7). As expected, the number of components 
influenced the response, and the adolescents responded only against the antigens 
included in the booster dose. The antigen concentration also influenced the magnitude of 
the immune responses induced by the vaccine.  
 
The great impact that pertussis vaccines have on disease incidence is widely known. 
However, determination of the optimal type of vaccine is hampered by the variety in 
multiple factors such as the vaccine content, schedule, follow-up, and case criteria used 
in the different efficacy studies. Environmental factors such as natural immunity and 
under-reporting of pertussis introduce bias into the evaluations. In summary, Pa vaccines 
are efficient at reducing pertussis incidence, and a single dose of Pa vaccine has been 
shown to reduce the risk of severe disease in infants [138]. They also have an excellent 
safety profile with fewer side effects than Pw vaccines. However, the Pw vaccines are 
considered more efficacious (reviewed in [70, 136]), but their usage is impeded by their 
reactogenicity. This indicates that with improvement of the Pw vaccine safety profile 
this type of vaccine could be more efficient at inducing a strong immune response 
against pertussis.   
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Table 7. Vaccines included in the booster study. 
Antigen  
(per 0.5 mL) 
Tdap5b 
(TRIAXIS®) 
Tdap1c 
(diTekiBooster) 
Tetanus toxoid  5 Lfa 6.25 Lf 
Diphtheria toxoid 2 Lf 6.25 Lf 
Pertussis toxoid 2.5 µg 20 µg 
Filamentous hemagglutinin 5 µg - 
Pertactin 3 µg - 
Fimbriae 2 and 3 5 µg - 
Adjuvant Aluminium phosphate 
(0.33 mg Al) 
Aluminium hydroxide hydrate 
(0.5 mg Al) 
a Lf: Limit of Flocculation, b 5-component pertussis vaccine, c 1-component pertussis vaccine 
 
 
 
7.2 IMMUNE RESPONSES 
Cells belonging to the innate immune system help by controlling the pertussis infection 
(reviewed in [139]) and DCs and macrophages are detected early in the infection. 
Macrophages contribute to the protective immunity against pertussis and engulf and 
destroy the bacteria. Depending on the stimuli, DCs have been shown to induce TH1-, 
TH17-, and Treg-cell responses in pertussis infections and thus play an important role in 
modulating the immune response ([140, 141] and reviewed in [139]). 
  
Natural pertussis infections and Pw vaccines induce similar TH1-type responses [142-
145], but Pa vaccines induce a more mixed TH2/TH1-type response [146-150] (Figure 7). 
TH1-type responses mediated by IFN-γ are important for resolving pertussis infections, 
and mice lacking IFN-γ are highly susceptible to lethal pertussis infections [151]. The 
TH2-type of response seems to play a minor role in protection against natural infection. 
Children infected with pertussis do not induce a TH2-type response [145], and in mice 
antibodies offer no major impact on bacterial clearance [152]. However, antibodies are 
thought to contribute to immunity by neutralization, opsonisation, and inhibition of 
pathogen binding to the host [153].  
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7.2.1 B-cell responses  
The traditional way to evaluate B-cell responses after pertussis vaccination is to measure 
antibody levels in serum, but not much focus has been on cellular B-cell responses. In 
studies including cell-mediated immunity, the focus has been mainly on T-cell responses 
[100, 154-156]. However, more data are emerging about the cellular B-cell responses 
after infection and vaccination against various pathogens, including pertussis [22-25, 
27].  
 
There is increasing evidence that B cells are important for efficient protection against 
pertussis. Mouse studies have shown a protective role for B cells without the influence 
of antibodies [152, 157], and mice with a depleted B-cell pool were less efficient at 
clearing a pertussis infection compared to immunocompetent mice [144]. In a B. 
bronchiseptica model, the shedding of bacteria was negatively correlated with 
Figure 7. Immune responses induced by pertussis infection or vaccination. The dendritic cells (DCs) 
take up bacteria or antigen and present it to naïve T cells. A. Natural pertussis infection and whole-
cell pertussis (Pw) vaccines lead to a TH1-type response where TH1 cells secrete interferon gamma 
(IFN-γ) and activate naïve B cells into memory B cells and long-lived plasma cells (LLPC). The 
macrophages (mɸ) are also activated and engulf bacteria, which leads to intracellular killing, but 
intracellular survival of B. pertussis is also seen. TH17 cells are also activated and contribute to 
bacterial clearance and other pro-inflammatory responses. B. Acellular pertussis (Pa) vaccines with 
alum as the adjuvant induce a more mixed TH2/TH1-type response with strong activation of B cells 
and antibody production. Blue: T cells, Green: B cells. Adapted from [3]. 
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increasing levels of B cells in the nasal cavities of mice. This decrease was, however, 
also influenced by T cells and antibodies [125]. Apart from being effector cells, B cells 
also function as APCs. Mice with deficient B-cell compartments or lacking MHCII-
expression by B cells have been shown to have impaired CD4+ T-cell proliferation and 
differentiation following viral infections [158, 159], and this highlights the contribution 
of the B-cell APC function. This demonstrates that the B cells most likely play multiple 
roles in the protection against pertussis and other pathogens. Limiting the evaluation of 
B-cell responses to only serology could be disadvantageous because immune responses 
would go undetected.  
 
Whereas other pathogens induce strong, stable B-cell responses after infection or 
vaccination [20, 23], pertussis does not seem to evoke high numbers of memory B cells 
after vaccination [22, 160] and is generally considered to be a poor immune inducer [89, 
161]. In a comprehensive study by Stenger et al., discrepancies in the B-cell response 
were identified in mice vaccinated and boosted with either the Pa or Pw vaccine [162]. 
Following the vaccination and booster, pertussis-specific serum IgG levels, plasma cells 
in bone marrow, and splenic memory B cells increased. Interestingly, following the peak 
levels, the pertussis-specific serum IgG decreased but the plasma cell levels increased, 
and this indicates an imbalance in the number of plasma cells and antibody secretion. 
The splenic memory B cells dropped to background levels, but their numbers could be 
rapidly increased with revaccination or antigen challenge. Curiously, this induction did 
not result in increased serum IgG levels. This led the authors to conclude that a plausible 
reason for the poor immunological response induced by pertussis might be due to a 
combination of poor production of antibody by plasma cells in the bone marrow and 
malfunction of the anamnestic memory B-cell response.  
 
Evaluations of long-term B-cell responses in humans are generally limited to peripheral 
blood with a few exceptions [28]. The spleen is the major reservoir for memory B cells, 
and memory B-cell frequencies are very low in peripheral blood [28, 163]. In the two 
clinical studies included in this thesis (papers II–IV), we measured the presence of 
memory B cells and antibody levels in blood both pre- and post-vaccination. The studies 
were not designed for long-term evaluation of the B-cell response following pertussis 
vaccination. The BPZE1 study did, however, have a follow-up of 6 months that enabled 
a slightly longer evaluation compared to the booster study with only a 4–6 week follow-
up (papers III and IV, respectively). The maintained or increased levels of serum IgG at 
5–6 months post BPZE1 vaccination in the colonized (culture-positive) subjects is 
indicative of an active pool of LLPCs (see Figure 8). The decrease in memory B cells 
after peak levels at day 28 is in agreement with other studies [20, 105, 164] and was 
expected because memory B cells home to the SLO and do not circulate extensively. 
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Encouragingly, although the memory B-cell levels had declined at 6 months, some 
subjects still had elevated levels compared to pre-vaccination, which indicates an 
increased memory B-cell pool.  
 
 
Figure 8. The B-cell responses detected in the seven culture-positive subjects in 
the BPZE1 study (from paper III). 
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In the short follow-up of the booster study, the subjects were found to respond similarly 
with antigen-specific memory B cells and serum IgG, and significant correlation could 
be detected for the 1-component group (Figure 9). However, this response was detected 
during the time when the acute response is still detectable in human blood [165] and, 
therefore, does not truly reflect the long-term presence and relationship between 
memory B cells and serum IgG. 
 
The complexity and contributions of the immune responses induced by pertussis remain 
to be elucidated. The fact that even a natural infection induces a relatively short-lived 
protection indicates that B. pertussis itself is highly evolved to escape strong immune 
recognition. Circumventing these obstacles is a challenge for optimizing the protection 
against pertussis.  
 
 
 
 
 
 
 
 
 
Figure 9. Correlation between the memory B-cell response and the serological response 
detected in the booster study (from paper IV). A significant correlation (Spearman r=0.7314) 
could be detected only in the PT-specific response for the 1-component vaccine group. 
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7.2.2 Comparison between a live, attenuated whole-cell vaccine and Pa 
vaccines  
This thesis included the evaluations of a live, attenuated vaccine (BPZE1, papers II and 
III) and two Pa vaccines (1- and 5-component, paper IV). In both studies, vaccine-
induced responses were evaluated pre-vaccination and 28–42 days post-vaccination with 
respect to pertussis-specific serum IgG levels (detected by ELISA) and IgG-producing 
memory B cells (detected by ELISpot). It could be rightfully argued that the large 
differences between the two studies and study populations do not allow for a comparison 
between the two types of vaccines. Because clinical trials on live, attenuated pertussis 
vaccines are rare, however, this is a good opportunity to reflect upon the similarities and 
differences between the two types of vaccines. Listed below are the major discrepancies 
between the studies:   
1. Previous vaccination scheme. The BPZE1 individuals (aged 19–34 years) had not 
received any previous pertussis vaccination but were not considered naïve, meaning that 
all had pertussis specific antibodies pre-vaccination. The adolescents (aged 14–15 years) 
that received the Pa vaccines had a primary vaccination consisting of three DTPa doses 
at 3, 5, and 12 months and an additional Tdap booster at 5½ years.  
2. Administration route. BPZE1 was given intranasally, but Pa vaccines were given 
parenterally. 
3. Adjuvants. The BPZE1 vaccine did not contain any adjuvant, but the Pa vaccines given 
to the adolescents contained alum. 
4. Number of subjects. See Table 8 for subjects included in the comparison. In the BPZE1 
study, only seven subjects were colonized by the bacteria and exhibited a pertussis-
specific response and were thus eligible for comparison. The variation in the number of 
included adolescents for memory B-cell responses was due to limited availability of 
cells.  
5. Antigen concentration and content. Because BPZE1 is a whole-cell vaccine, the exact 
antigen concentration is not determinable, but all antigens included in the comparison 
are expressed by the bacteria. The antigen content and concentration varied between the 
Pa vaccines (see Table 7 in §7.1).  
 
Table 8. Number of subjects included for the comparison between BPZE1 and acellular pertussis 
(Pa) vaccines (1- or 5-component). 
  BPZE Pa1 Pa5 
Memory B-cell ELISpot PT 7 18 16 
FHA 7 8 8 
PRN 7 11 11 
Serum IgG ELISA PT 7 18 16 
FHA 7 18 16 
PRN 7 18 16 
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The intranasal vaccination with the BPZE1 vaccine induced a strong memory B-cell 
response against all included antigens (Figure 10). The adolescents responded against 
the antigen included in their booster dose. However, the 5-component group did not 
mount a strong PT-specific response. The PT-specific serum response was similar 
between the BPZE1 and the 5-component vaccine but lower compared to the 1-
component vaccine. The 5-component vaccine induced higher antibody levels against 
FHA and PRN compared to the intranasal whole-cell vaccine. The inclusion of the TH2-  
skewing adjuvant alum in the Pa vaccine and the differences in the previous vaccination 
history could explain this. Although the BPZE1 vaccine is not yet optimized, it appears 
to induce an immune response more similar to that seen after a natural infection 
compared to the Pa vaccine.  
 
 
 
 
 
 
Figure 10. A comparison of the responses detected after vaccination with a live, attenuated whole-
cell (Pw) vaccine (BPZE1) and two acellular pertussis (Pa) vaccines (1- and 5-component). The 
results were obtained in two very different studies abrogating any true conclusions, but the Pw 
vaccine seems to induce a stronger cellular response compared to serological response, whereas 
the Pa vaccine induces a more mixed cellular and serological response.  
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7.3 CORRELATES OF PROTECTION 
Several attempts have been made to estimate a correlate of protection against pertussis, 
but no consensus has been reached. Fim antibodies have been shown to impair B. 
pertussis attachment to respiratory epithelial cells [68] and were shown to offer 
protection at a group level in an early Pw vaccine study [166]. Later, a more complex 
correlation was shown where PRN, Fim, and PT antibodies correlate either singly or a 
synergistically with protection at a group level [80, 167-170]. Cellular immunity has 
also been shown to be essential in pertussis protection, which suggests that several 
factors contribute to the protection against pertussis and impedes the conclusion 
regarding a single correlate of protection.  
 
In the BPZE1 study, an interesting finding regarding the antibody specificity and 
protection against colonization was discovered (paper II). An anti-PT level above 20 
IU/mL was set as an exclusion criterion to account for any recent pertussis infection, and 
no other antibody specificity was regarded. However, when analysing the pre-
vaccination samples in the high-dose group, the culture-negative subjects were found to 
have significantly higher antibody levels compared to the culture-positive subjects (see 
Figure 11), and this clearly indicates a protective role of antibodies with specificities 
other than PT against BPZE1 colonization.  
 
 
Figure 11. The pre-vaccination levels of pertussis-specific antibodies in sera in the culture-
positive (n = 5) and the culture-negative subjects (n = 7) in the high-dose group in the BPZE1 
study (from paper II). The culture-negative subjects had significantly higher levels compared 
to the culture-positive subjects against all antigens except PT. This indicates that PRN-, FHA-, 
and Fim-specific antibodies might offer protection against B. pertussis colonization.  
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7.4 NEW APPROACHES FOR PROTECTION AGAINST PERTUSSIS 
At present, there is no effective strategy to prevent pertussis in the most vulnerable, 
unvaccinated infants in their first months of life. Optimizing the current vaccination 
scheme for efficient protection in this age group is, therefore, of high priority.  
 
7.4.1 Cocoon, maternal, and neonatal vaccination strategies 
The cocoon strategy involves vaccination of the infant’s closest contacts right after birth. 
Because parents and other close household contacts are known sources of infant 
pertussis, this strategy is thought to limit transmission to the infant during the first 
critical months. Although this strategy is likely to have an impact on infant pertussis, it 
does not prevent transmission from casual contact that infants are also exposed to [107, 
171].   
 
Inducing protective antibody levels in the infants via maternal vaccination is an 
alternative for infant protection. In a baboon model, maternal Pa vaccination was shown 
to protect against disease in infants; however, this protection did not prevent 
colonization following pertussis challenge [172]. In humans, maternal vaccination 
against pertussis has been found safe [173, 174] and is recommended in several 
countries (summarized in [175]). The low adherence to the program is a concern, 
however (reviewed in [176]). 
 
A more direct strategy to evoke the infant immune system is neonatal vaccination. Pw 
and Pa vaccination in infant mice induces protective immunity towards pertussis 
challenge [177], and in young infants, a natural pertussis infection or Pw vaccination 
promotes a TH1-type response [143]. Even premature infants mount pertussis-specific 
responses following vaccination [178], which demonstrates the maturity of the infant 
immune system. Pa vaccination of neonates induces a strong TH2-type response [179] 
but is safe and immunogenic [180-182]. Studies in neonatal baboons also showed that 
Pa vaccination induced protection against pertussis disease but not against colonization 
[172].  
 
7.4.2 Novel vaccines 
An alternative approach to achieving better vaccine-induced protection for infants is 
optimization of the currently available vaccines. Increasing vaccine-efficacy could lead 
to a reduction of pertussis incidence in the general population and thus reduce 
transmission to infants. Suggestions for improvement have been to develop Pw vaccines 
with less reactogenicity, to add more antigens to the Pa vaccine, and/or to include other 
adjuvants to better boost and direct the immune responses.  
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Pa vaccine efficacy is believed to improve by inclusion of adjuvants that induce a more 
TH1-skewed immune response. Addition of the TLR9 agonist CpG to an alum-adjuvant 
Pa vaccine has given encouraging results for a more balanced induction of the TH1/TH2-
type response in mice [183, 184]. Therefore, adding additional adjuvants to the licenced 
vaccines could provide protection that is more efficient. In parallel, the inclusion of 
more antigens is also believed to increase efficacy because it would induce a broader 
response. This is supported by the findings that vaccine efficacy increases with the 
number of antigens included [133, 135, 136]. A possible candidate for inclusion in the 
Pa vaccines is ACT. Adding ACT to the Pa vaccine enhances immune responses in mice 
[185], and ACT on its own induces protective immunity [186]. All together, the efficacy 
of Pa vaccines is likely to be improved with novel formulations. New Pw vaccines are 
being investigated due to their high efficacy, but the key issue is to reduce side effects.  
 
7.4.3 BPZE1  
BPZE1 is designed to mimic a natural infection and is intended to be offered as a birth 
dose to complement the current vaccination program. Several pre-clinical studies have 
investigated the safety and immunogenicity of BPZE1. It is genetically stable with no 
reversion despite numerous in vitro and in vivo passages [187]. BPZE1 colonization in 
adult and infant mice is similar to virulent strains but without any pathological changes 
[69]. One dose of BPZE1 offers better protection compared to two doses of Pa vaccine 
[69], and this protection is maintained up to one year after vaccination [188, 189]. In vivo 
studies in mice and an in vitro study with human DCs demonstrate the induction of strong 
TH1- and TH17-type responses similar to natural infection responses. Specific B cells and 
antibodies are also induced by BPZE1 and contribute to protection [190].  
 
Mucosal vaccination with a live, attenuated pertussis vaccine has not been performed 
before in a clinical setting. Killed Pw vaccines have, however, been shown to be 
immunogenic when administered intranasally with a spray [191, 192]. In addition, 
intranasal vaccination with a cholera subunit vaccine induced strong, long-lasting 
antibody responses both in serum and in nasal secretions [193].  
 
Similar to natural infection, BPZE1 was found in nasopharynx samples between day 4 
and day 28 after vaccination in the culture-positive subjects (paper II)  [194], and this 
demonstrates full functionality of the modified bacteria in humans. However, because 
only 7 of the 36 subjects that received the active vaccine were colonized by the bacteria, 
the vaccine response seemed to be suboptimal. Five of the culture-positive subjects were 
in the high-dose group, which indicates a dose-dependent vaccine response. Similar 
results were also found in the pre-clinical studies where vaccine efficacy and immune 
responses increased with BPZE1 dosage [195]. An explanation for the low vaccine 
 42 
response in humans could be the low cfu/dose. Because BPZE1 had not been used in 
humans before, the dosages were estimated based on results obtained in mouse studies 
[195]. A dose of 106 cfu was well tolerated in mice, but the maximum dose in the 
clinical trial was only 107 cfu (paper II). In a baboon animal model, a dosage of 109–1010 
cfu of virulent B. pertussis is used to infect animals [123], and an intranasal vaccine 
against kennel cough includes ≥108 cfu/dose. This indicates that higher dosages could be 
tested in humans to increase the vaccine response. 
 
 
 
 
From the results obtained in the BPZE1 study (reported in papers II and III), we 
concluded that the BPZE1 vaccination was safe for human use and that colonized 
subjects induced strong and long-term pertussis-specific serological and B-cell 
responses (as measured up to 6 months post-vaccination; see Figure 12). Included in the 
Figure 12. B-cell responses from the BPZE1 trial. Culture-positive subjects (n = 7) had increased 
pertussis-specific serum IgG levels and memory B-cell responses following BPZE1 vaccination. 
Memory B-cell response peaked at day 28 but declined 150–180 days post-vaccination. Serum 
IgG antibody levels increased after 7–14 days and were maintained or increased 150–180 days 
post-immunization. No response was seen in the culture-negative group (n = 29). Median values 
with max and min values are shown.  
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study design but not reported in the papers were the T-cell responses evoked by BPZE1. 
The presence of pertussis-specific IFN-γ and IL-2 secreting cells were evaluated by T-
cell ELISpot on days 0, 14, and 28 and 5–6 months post-vaccination. Due to a 
methodological error, only two culture-positive subjects (no. 110 from the low-dose 
group and no. 228 from the medium-dose group) had available samples from all time 
points. According to established criteria (see Figure 13), subject no. 110 responded with 
IL-2-secreting T cells against all antigens tested for, but only the PT-specific IFN-γ 
responses met the response criteria. Subject no. 228 produced both IFN-γ and IL-2 
against FHA and PT but did not meet the response criteria for PRN (see Figure 13). 
Parenteral administration of pertussis vaccines has been demonstrated to induce a strong 
IFN-γ response one month after immunization in humans [150, 196, 197], and mouse 
studies of BPZE1 have shown that vaccination induces protective levels of splenic CD4+ 
T cells [190]. More subjects would have enabled a stronger conclusion, but these limited 
results do indicate that BPZE1 vaccination induces pertussis-specific T-cell responses in 
humans.  
 
 
 
 
Pertussis-specific serum IgA levels were also determined (see Figure 14). The culture-
positive subjects responded with IgA against all included antigens except PRN. The 
culture-negative group was non-responsive throughout the trial except for some 
fluctuations in PRN. Even though increases were seen for the culture-positive group, the 
Figure 13. IFN-γ- and IL-2-secreting T cells at different time points following BPZE1 vaccination in two 
culture-positive subjects. Subject no.110 responded with IL-2-specific T cells against all antigens but 
with IFN-γ-specific T cells only against PT. Subject no. 228 responded with both IL-2- and IFN-γ-
specific T cells against FHA and PT but did not meet the response criteria for PRN due to high pre-
vaccination levels. Response criteria were set to be more than double the number of spots post-
vaccination compared to pre-vaccination and above 55 spots/106 PBMC for IFN-γ. For IL-2, no cut-off 
value was established. 
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study design but not reported in the pa ers were the T-cell responses voked by BPZE1. 
The presence of pertussi -specific IFN-γ and IL-2 secreting cells were evaluated by T-
cell ELISpot n days 0, 14, and 28 and 5–6 months post-vaccination. Due to a 
method logical error, only two cult re-positive subjects (no. 110 from the low-dose 
group and no. 228 from the medium-dose group) had v il ble samples from all time 
points. According to established criteria (see Figure 13), subject no. 110 responde  with 
IL-2-secreting T cells ag inst all antigens test d for, but only the PT-specific IFN-γ 
responses met the r sponse criteria. Subject no. 228 produced both IFN-γ and IL-2 
ag inst FHA and PT but did not meet the r sponse criteria for PRN (see Figure 13). 
Parenteral dministration of pertussi  vaccines has been demonstrated to induce a strong 
IFN-γ response one month after immunization i  humans [150, 196, 197], and mouse 
studies of BPZE1 have shown that vaccination i duces protective l v ls of splenic CD4+ 
T cells [190]. More subjects would have enabled a stronger conclusion, but these limited 
results do indicate that BPZE1 vaccination i duces pertussi -specific T-cell responses in 
humans.  
 
 
 
 
Pertussi -specific serum IgA lev ls were also determined (see Figure 14). The cult re-
positive subjects responde  with IgA ag inst all include  antigens except PRN. The 
cult re-negative group was no -responsive throughout the trial except for some 
fluctuations in PRN. Even though increases were s en for the cult re-positive group, the 
Figure 13. IFN-γ- and IL-2-secr ting T cells at different time points following BPZE1 vaccination in two 
culture-positive subjects. Subject no.110 responde  with IL-2-specifi  T cells ag inst all ntigens but 
with IFN-γ-specifi  T cells only ag inst PT. Subject no. 228 responde  with both IL-2- and IFN-γ-
specifi  T cells ag inst FHA and PT but did not meet the r sponse criteria for PRN due to hig  pre-
vaccination levels. Response criteria were s t to be more than double the number of spots post-
vaccination compared to pre-vaccination a d above 55 spots/106 PBMC for IFN-γ. For IL-2, no cut-off 
value was e tablished. 
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differences were not statistically significant. This result is most likely influenced by the 
high antibody levels in the culture-negative group.  
 
In conclusion, the results from the first human study of the novel BPZE1 vaccine strain 
are promising, and the vaccine strain was found to be safe and immunogenic. However, 
the vaccine is not yet optimized, and the dosages and vaccine formulation need to be 
improved. With these changes, the true potential of the novel vaccine strain can be 
established in future studies.  
 
 
 
 
 
Figure 14. Pertussis-specific serum IgA levels in culture-positive (n = 7) and culture-negative (n = 
29) subjects. Increases in the PT-, FHA-, and Fim-specific antibody levels were detected at day 28 
post-immunization in the culture-positive group, but the increases were not significantly higher 
compared to culture-negative subjects. Median values with min and max values are shown.  
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8 CONCLUDING REMARKS  
 
Despite years of vaccination, B. pertussis is still a concern to the general population and 
a serious threat to unvaccinated infants. Numerous studies have evaluated the efficacy of 
pertussis vaccines, but comparison between studies is often hampered by the differences 
in the study designs. The optimization of the B-cell ELISpot protocol described in this 
thesis clarified the impact that the inclusion of the optimal activators and detection 
system has on the detection sensitivity of a positive result. A strong consensus on 
standardised protocols and controls would greatly facilitate the analysis of a broader 
array of data obtained in different studies.  
 
Traditionally, evaluation of pertussis has centred on serological antibody responses, but 
there is no established single serological correlate of protection. The protection against a 
natural pertussis infection is multifaceted, and there is still much to learn about the 
pertussis-specific immune response. In the two clinical trials included in this thesis, we 
detected strong and broad memory B-cell and serological antibody responses following 
both mucosal and parenteral pertussis immunization. This shows that without a broad 
evaluation, vaccine-induced responses would go undetected. Therefore, it seems 
beneficial to investigate several different arms of the immune responses to better 
comprehend the pertussis-induced immunity.  
 
Within the scope of this thesis, we have reported on an optimized B-cell ELISpot and 
the immunogenicity after two types of pertussis vaccination (acellular and live, 
attenuated) in two different Swedish populations (previously vaccinated and 
unvaccinated). Although the vaccines were found safe and immunogenic, the analyses 
did have limitations. In general, few samples from subjects were available for each 
analysis due to low vaccine response in the BPZE1 study and low cell availability for 
the boostered adolescents. More subjects would have strengthened the statistical 
evaluation of the responses.  
 
Most of the results reported in this thesis were obtained within the scope of clinical 
trials, which, to some extent, was also a limiting factor. Clinical trials are highly 
regulated to protect the participants and are meticulously planned. No deviation from the 
clinical study protocol or the informed consent document is allowed, which results in an 
inflexible analysis plan after approval of the study. Moreover, the clinical trials included 
analyses of several immune parameters but only a limited sample size, which impeded 
an extensive evaluation of a specific response. The methodological part of this thesis is, 
therefore, limited because generally only ELISpot and ELISA were implemented. 
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Working with clinical trials does, however, require specific expertise. All of the work 
performed for this thesis, from the planning to the archiving of results, was done 
according to Good Clinical and Laboratory Practice (GCLP). This is a detailed and time-
consuming process but vital for quality-assured results. These regulations should be 
applied to all types of clinical research, and experience with GCLP is a highly valuable 
asset. The GCLP knowledge gained within the scope of this thesis is believed to 
compensate for the lack of methodological variation.  
 
Increasing the efficacy of pertussis vaccines is an urgent matter. Improving the 
reactogenicity of Pw vaccines and switching back to whole-cell vaccines should lead to 
better efficacy, as would including better adjuvants or more antigens in the available Pa 
vaccines. Increasing efficacy of available vaccines would lead to an increased protection 
in the population and reduced pertussis transmission to infants. However, protecting the 
infant by adjusting its environment is complicated, and a more appealing approach is to 
improve the infant’s own protection. Neonatal vaccination is, therefore, a hopeful 
approach, especially in combination with more efficient vaccines.  
 
Eradication of pertussis is an unlikely solution today. Therefore, the focus lies on 
optimizing protection for infants and small children. With more knowledge about the 
immune responses required for protection, we can also learn how to optimize the 
vaccines that target pertussis. With patience, open-mindedness, and collaboration, the 
riddle of pertussis can be solved.   
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